📣 VC round data is live. Check it out!
- Public Comps
- Terumo
Terumo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Terumo and similar public comparables like Straumann Group, Steris, West Pharma, Smith & Nephew and more.
Terumo Overview
About Terumo
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo’s revenue.
Founded
1921
HQ

Employees
30.7K
Website
Sectors
Financials (LTM)
EV
$19B
Valuation Multiples
Start free trialTerumo Financials
Terumo reported last 12-month revenue of $7B and EBITDA of $2B.
In the same LTM period, Terumo generated $4B in gross profit, $2B in EBITDA, and $877M in net income.
Revenue (LTM)
Terumo P&L
In the most recent fiscal year, Terumo reported revenue of $7B and EBITDA of $2B.
Terumo is profitable as of last fiscal year, with gross margin of 50%, EBITDA margin of 23%, and net margin of 11%.
Financial data powered by Morningstar, Inc.
Terumo Stock Performance
Terumo has current market cap of $18B, and enterprise value of $19B.
Market Cap Evolution
Terumo's stock price is $12.48.
Terumo share price increased by 0.1% in the last 30 days, and decreased by 25.5% in the last year.
Terumo has an EPS (earnings per share) of $0.54.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19B | $18B | -0.9% | 0.1% | -6.1% | -25.5% | $0.54 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTerumo Valuation Multiples
Terumo trades at 2.7x EV/Revenue multiple, and 11.0x EV/EBITDA.
EV / Revenue (LTM)
Terumo Financial Valuation Multiples
As of May 12, 2026, Terumo has market cap of $18B and EV of $19B.
Terumo has a P/E ratio of 21.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Terumo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Terumo Margins & Growth Rates
Terumo grew revenue by 0% and EBITDA by 5% in the last fiscal year.
In the most recent fiscal year, Terumo reported gross margin of 50%, EBITDA margin of 23%, and net margin of 11%.
Terumo Margins
Terumo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Terumo Operational KPIs
Terumo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Terumo's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Terumo's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Terumo Competitors
Terumo competitors include Straumann Group, Steris, West Pharma, Smith & Nephew, Fresenius Medical Care, Fresenius, Baxter International, AptarGroup, Mindray and Avantor.
Most Terumo public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.0x | 5.0x | 16.5x | 16.4x | |||
| 3.9x | 3.6x | 15.8x | 12.8x | |||
| 7.3x | 7.1x | 28.8x | 27.1x | |||
| 2.5x | 2.4x | 9.7x | 9.4x | |||
| 1.0x | 1.0x | 5.4x | 5.4x | |||
| 1.4x | 1.3x | 8.3x | 8.2x | |||
| 1.5x | 1.5x | 7.3x | 7.5x | |||
| 2.3x | 2.3x | 10.6x | 10.8x | |||
This data is available for Pro users. Sign up to see all Terumo competitors and their valuation data. Start Free Trial | ||||||
Terumo M&A Activity
Terumo has acquired 4 companies to date.
Last acquisition by Terumo was on August 23rd 2025. Terumo acquired OrganOx for $2B (EV/Revenue multiple of ).
Latest Acquisitions by Terumo
| Description | OrganOx is an Oxford-headquartered medical device company that commercializes the Metra system for normothermic machine perfusion of donor livers during transplantation. Approved by FDA in 2020 and CE marked since 2018, the technology maintains organs at body temperature for up to 24 hours, improving utilization rates by 30 percent. OrganOx systems operate in 50 US and European centers, partnering with NHS Blood and Transplant. | Health Outcomes Sciences is a Boston-based developer of clinical decision-support software. The company translates research into tools like the validated QRisk model for cardiovascular risk prediction and EchoInsight for echocardiography analysis. Licensed to hospitals and EHR vendors such as Epic, its platforms quantify comorbidities and genomic factors to personalize treatments in cardiology and oncology. | Quirem Medical is a Netherlands-based healthcare company developing Holmium-166 microspheres for Selective Internal Radiation Therapy targeting liver tumors. Its CE-marked products include QuiremScout for scouting, QuiremSpheres for treatment, and Q-Suite dosimetry software, enabling visualization, quantification, patient selection, planning, and verification in oncology centers worldwide. | — |
| HQ Country | ||||
| HQ City | Oxford | Phoenix, AZ | Deventer | — |
| Deal Date | 23 Aug 2025 | 24 Feb 2021 | 15 Jul 2020 | 1 Jan 2017 |
| Valuation | $2B | undisclosed | $56M | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Terumo acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Terumo Investment Activity
Terumo has invested in 5 companies to date.
Latest investment by Terumo was on March 4th 2024. Terumo invested in Diabeloop in their $16M Undisclosed stage round (EV/Revenue multiple of ).
Latest Investments by Terumo
| Description | Diabeloop is a Grenoble-headquartered medtech company developing closed-loop artificial pancreas systems for type 1 diabetes management. Its DBLG1 algorithm integrates CGM data from Dexcom and insulin pumps from Roche, automating deliveries via smartphone app. FDA-cleared in 2023, the Grenoble-based firm founded in 2015 conducts trials across Europe and the US. Diabeloop partners with Philips and Asahi Kasei Med for distribution in 20 countries. | Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease. | Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product. | Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease. | |
| HQ Country | |||||
| HQ City | Grenoble | — | — | — | |
| Deal Date | 4 Mar 2024 | 30 Jan 2022 | 4 Dec 2020 | 19 Jun 2019 | |
| Round | Undisclosed stage | Series D | Undisclosed stage | Strategic investment | |
| Raised | $16M | $110M | $19M | $35M | |
| Investors | AGIR a Dom; Cemag Invest; CERITD; Crédit Agricole; InnovaCom; KREAXI; LBO France; ODYSSEE VENTURE; Supernova Invest; Terumo; UI Investissement | Medtronic; Perceptive Advisors; RTW Investments; SternAegis; Terumo | Asahi Intecc; Dai-Dan; Kyoto University Innovation Capital; StemCell Institute; Taiko Pharmaceutical; Terumo | Terumo | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Terumo investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Terumo
| When was Terumo founded? | Terumo was founded in 1921. |
| Where is Terumo headquartered? | Terumo is headquartered in Japan. |
| How many employees does Terumo have? | As of today, Terumo has over 30K employees. |
| Who is the CEO of Terumo? | Terumo's CEO is Hikaru Samejima. |
| Is Terumo publicly listed? | Yes, Terumo is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Terumo? | Terumo trades under 4543 ticker. |
| When did Terumo go public? | Terumo went public in 1982. |
| Who are competitors of Terumo? | Terumo main competitors include Straumann Group, Steris, West Pharma, Smith & Nephew, Fresenius Medical Care, Fresenius, Baxter International, AptarGroup, Mindray, Avantor. |
| What is the current market cap of Terumo? | Terumo's current market cap is $18B. |
| What is the current revenue of Terumo? | Terumo's last 12 months revenue is $7B. |
| What is the current revenue growth of Terumo? | Terumo revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Terumo? | Current revenue multiple of Terumo is 2.7x. |
| Is Terumo profitable? | Yes, Terumo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Terumo? | Terumo's last 12 months EBITDA is $2B. |
| What is Terumo's EBITDA margin? | Terumo's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Terumo? | Current EBITDA multiple of Terumo is 11.0x. |
| What is the current FCF of Terumo? | Terumo's last 12 months FCF is $566M. |
| What is Terumo's FCF margin? | Terumo's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Terumo? | Current FCF multiple of Terumo is 34.3x. |
| How many companies Terumo has acquired to date? | As of May 2026, Terumo has acquired 4 companies. |
| What was the largest acquisition by Terumo? | $2B acquisition of OrganOx on 23rd August 2025 was the largest M&A Terumo has done to date. |
| What companies Terumo acquired? | Terumo acquired OrganOx, Quirem Medical, Bolton Medical, Inc, and Health Outcomes Sciences. |
| In how many companies Terumo has invested to date? | As of May 2026, Terumo has invested in 5 companies. |
| What was the last Terumo investment? | On 4th March 2024 Terumo invested in Diabeloop, participating in a $16M Undisclosed stage round, alongside AGIR a Dom, Cemag Invest, CERITD, Crédit Agricole, InnovaCom, KREAXI, LBO France, ODYSSEE VENTURE, Supernova Invest, and UI Investissement. |
| In what companies Terumo invested in? | Terumo invested in Orchestra BioMed, Vascutek, Cuorips, Diabeloop, and ReThink Medical. |
See public comps similar to Terumo
Lists including Terumo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




